Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Consulting agrmnt
Appointed director
Employment agrmnt
Marker Therapeutics, Inc. (MRKR) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 8-K Quarterly results
Docs: "Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update"
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/07/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program Houston, TX – August 7, 2023 – Marker Therapeutics, Inc. , a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced non-clinical data of its lead multi-tumor-associated antigen -specific T cell product candidate, MT-401, in an Off-the-Shelf setting and provided an update on clinical readiness for the OTS program. Non-Clinical Proof-of-Concept Data of MT-401 OTS"
07/10/2023 8-K Quarterly results
07/05/2023 3 Lurier Eliot M (Interim CFO) has filed a Form 3 on Marker Therapeutics, Inc.
06/30/2023 8-K Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits  Interactive Data
Docs: "Unaudited Pro Forma Condensed Consolidated Balance Sheet as of March 31, 2023 and Unaudited Pro Forma Condensed Consolidated Statements of Operations for the Year Ended December 31, 2021, the Year Ended December 31, 2022 and the Three Months Ended March 31, 2023"
06/12/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial"
06/09/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
06/08/2023 4 Eansor Norman David (Director) has filed a Form 4 on Marker Therapeutics, Inc.
Txns: Bought 14,285 shares @ $17.5, valued at $250k
Gifted 14,285 shares @ $0
Gifted 7,142 shares @ $0
Granted 8,000 options to buy @ $1.72, valued at $13.8k
06/08/2023 4 Knobil Katharine (Director) has filed a Form 4 on Marker Therapeutics, Inc.
Txns: Granted 8,000 options to buy @ $1.72, valued at $13.8k
06/08/2023 4 Wilson John Robert (Director) has filed a Form 4 on Marker Therapeutics, Inc.
Txns: Granted 8,000 options to buy @ $1.72, valued at $13.8k
06/08/2023 4 ELMS STEVE (Director) has filed a Form 4 on Marker Therapeutics, Inc.
Txns: Granted 8,000 options to buy @ $1.72, valued at $13.8k
05/31/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells"
05/11/2023 4 Vera Juan (President and CEO) has filed a Form 4 on Marker Therapeutics, Inc.
Txns: Granted 100,000 options to buy @ $1.42, valued at $142k
05/08/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer"
05/01/2023 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "MARKER THERAPEUTICS announces comprehensive non-dilutive AGREEMENT WITH CELLREADY&trade"
03/22/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
03/22/2023 8-K Quarterly results
03/22/2023 10-K Annual Report for the period ended December 31, 2022
03/16/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/01/2023 4 Hoang Tsvetelina P (VP, Research and Development) has filed a Form 4 on Marker Therapeutics, Inc.
Txns: Granted 33,159 options to buy @ $2.14, valued at $71k
03/01/2023 4 Koneru Mythili (Chief Medical Officer) has filed a Form 4 on Marker Therapeutics, Inc.
Txns: Granted 51,918 options to buy @ $2.14, valued at $111.1k
03/01/2023 4 Loiacono Michael (Chief Accounting Officer) has filed a Form 4 on Marker Therapeutics, Inc.
Txns: Granted 38,480 options to buy @ $2.14, valued at $82.3k
03/01/2023 4 Vera Juan (Chief Scientific Officer & COO) has filed a Form 4 on Marker Therapeutics, Inc.
Txns: Granted 46,487 options to buy @ $2.14, valued at $99.5k
03/01/2023 4 Szymanska Anna (Vice President, Quality) has filed a Form 4 on Marker Therapeutics, Inc.
Txns: Granted 29,947 options to buy @ $2.14, valued at $64.1k
03/01/2023 4 Agopyan Nadia (SVP, Regulatory Affairs) has filed a Form 4 on Marker Therapeutics, Inc.
Txns: Granted 34,154 options to buy @ $2.14, valued at $73.1k
01/26/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "Certificate of Amendment to Amended and Restated Certificate of Incorporation of Marker Therapeutics, Inc., effective January 26, 2023"
01/03/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
01/03/2023 EFFECT Form EFFECT - Notice of Effectiveness:
12/23/2022 S-1 Form S-1 - General form for registration of securities under the Securities Act of 1933:
12/13/2022 8-K Quarterly results
11/22/2022 8-K Quarterly results
11/10/2022 8-K Quarterly results
11/10/2022 10-Q Quarterly Report for the period ended September 30, 2022
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy